For example, disrupting PD-1/PD-L1 signal, a negative regulatory mechanism for T effector cells, is one of the most popular anti-tumor immunotherapies (Mahoney, Freeman & McDermott, 2015). This evidence concerns the gene CD274 and neoplasm.